SMS Pharmaceuticals Ltd 05 Nov 2026 12:00 AM
SMS Pharmaceuticals Ltd consolidated sales up 52.73% on year in Q3FY2026, net profit soared by 95.89%,
SMS Pharmaceuticals Ltd share price ticked higher by 2.47% to Rs 526.4 after the company`s net profit surged by 95.89% to Rs 39.57 crore, while revenue from operations gained significantly 52.73% to Rs 316.09 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.14%. It has marginally improved by 2.03% over last one week and crept higher by 1.77% in last one month while the market capitalization of SMS Pharmaceuticals Ltd has inched up 8.35% and 39.52% in the same period respectively. Profit before tax (PBT) of SMS Pharmaceuticals Ltd stood at Rs 52.82 crore in Q3 FY26, jumping 55.17% year-on-year, and surging by 94.12% quarter-on-quarter. EBITDA came in at Rs 66 crore, expanding by 41.30% YoY and rallying 69.12% sequentially. Total expenses surged 47.09% to Rs 258.88 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 168.08 crore, soaring by 23% YoY, while employee benefits expense was at Rs 27.26 crore, soaring 15.80% YoY. For the TTM ended FY26, revenue from operations grew 13.30% to Rs 886.87 crore, while net profit jumped 30.56% to Rs 88.0 crore, compared to previous TTM. EBITDA jumped by 13735% to Rs 162.93 crore, and PBT soared 26.32% to Rs 116.64 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 59.22 crore in FY26, as against Rs 81.71 crore in FY25. SMS Pharmaceuticals Ltd rallied 87.06% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 7.38% during the same period.
SMS Pharmaceuticals Ltd 04 Nov 2026 12:00 AM
SMS Pharmaceuticals Ltd consolidated sales up 52.73% on year in Q3FY2026, net profit soared by 95.89%,
SMS Pharmaceuticals Ltd share price inched up 1.87% to Rs 513.7 after the company`s net profit jumped 95.89% to Rs 39.57 crore, while revenue from operations increased sharply by 52.73% to Rs 316.09 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 4.49%. It has marginally improved by 1.84% over last one week and gained upto 1.37% in last one month while the market capitalization of SMS Pharmaceuticals Ltd has improved by 7.69% and 43.81% in the same period respectively. Profit before tax (PBT) of SMS Pharmaceuticals Ltd stood at Rs 52.82 crore in Q3 FY26, jumping 55.17% year-on-year, and expanding by 94.12% quarter-on-quarter. EBITDA came in at Rs 66 crore, rallying 41.30% YoY and surging by 69.12% sequentially. Total expenses surged 47.09% to Rs 258.88 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 168.08 crore, soaring by 23% YoY, while employee benefits expense was at Rs 27.26 crore, soaring 15.80% YoY. For the TTM ended FY26, revenue from operations rose 13.30% to Rs 886.87 crore, while net profit surged by 30.56% to Rs 88.0 crore, compared to previous TTM. EBITDA jumped by 13735% to Rs 162.93 crore, and PBT witnessed a strong rise of 26.32% to Rs 116.64 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 59.22 crore in FY26, as against Rs 81.71 crore in FY25. SMS Pharmaceuticals Ltd rallied 82.13% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.
SMS Pharmaceuticals Ltd 28 Oct 2026 12:00 AM
SMS Pharmaceuticals to review Q2 financial results at board meeting November 4, 2026,
SMS Pharmaceuticals Limited will hold a board meeting on Wednesday, November 4, 2026, to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Ltd. The company has closed the trading window for its equity shares for designated persons, including directors, from October 1, 2026, until November 6, 2026, and will reopen it on November 7, 2026.
SMS Pharmaceuticals Ltd 07 Oct 2026 12:00 AM
SMS Pharmaceuticals reports compliance confirmation from Aarthi Consultants for September 30, 2026,
SMS Pharmaceuticals Limited informed the BSE Limited and National Stock Exchange of India Ltd that it has received a certificate from Aarthi Consultants Private Limited, Hyderabad, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended September 30, 2026.
SMS Pharmaceuticals Ltd 24 Sep 2026 12:00 AM
SMS Pharmaceuticals closes trading window for insiders ahead of Q2/H1 results,
SMS Pharmaceuticals Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in the company`s shares will be closed for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the second quarter and half year ended September 30, 2026, in accordance with SEBI regulations and the company`s code of conduct.
Subscribe for our
newsletter
Open Account Now